Overview

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Safety, tolerability and efficacy of BI 655066 in male and female patients with moderate to severe psoriasis.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie
Collaborator:
Boehringer Ingelheim
Treatments:
Antibodies, Monoclonal